Nestlé va dezvolta noi produse pentru consumatorii de medicamente pentru slăbit

Nestlé aims to turn the rise of GLP-1 weight loss drugs into a business opportunity by developing products to counteract their side effects using AI. The company is concerned that appetite-suppressing medications could decrease demand for packaged foods and beverages. Nestlé's CTO, Stefan Palzer, stated that they are leveraging AI to analyze clinical research and create nutrient combinations tailored for GLP-1 users. The upcoming products may help mitigate side effects like muscle loss. Nestlé has also patented proprietary ingredient combinations to help reduce appetite among users after stopping GLP-1 treatments. Approximately 16 million Americans currently use GLP-1 medications, a number expected to rise significantly by 2030.